Literature DB >> 30051397

Heart Transplantation Survival and Sex-Related Differences.

Martina Previato1, Elena Osto2,3,4, Peter L M Kerkhof5, Gareth Parry6, Francesco Tona7.   

Abstract

Orthotopic heart transplantation (OHT) is the "gold standard" treatment for patients with end-stage heart failure, with approximately 5000 transplants performed each year worldwide. Heart transplantation survival rates have progressively improved at all time points, despite an increase in donor and recipient age and comorbidity and greater recipient urgency; according to the registry of the International Society of Heart and Lung Transplantation (ISHLT), the median survival of patients posttransplantation is currently 12.2 years.Long-term survival is sub-optimal, and outcomes after OHT remain constrained by the development of acute rejection and cardiac allograft vasculopathy (CAV). Moreover, donor organs are in short supply, making optimal organ utilization an ongoing priority. For these reasons, substantial interest continues to exist in identifying factors portending increased survival and improved organ utilization.

Entities:  

Keywords:  Allograft vasculopathy; Cardiac transplantation; Donor organ; Immunological difference; Microvasculopathy; Posttransplant mortality; Premenopausal female donor; Review; Sex mismatch; Transfusion history; United Network for Organ Sharing

Mesh:

Year:  2018        PMID: 30051397     DOI: 10.1007/978-3-319-77932-4_24

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  2 in total

1.  Case report on the importance of longitudinal analysis of left ventricular end-systolic volume, rather than ejection fraction, in a heart transplant patient.

Authors:  Peter L M Kerkhof; Guy R Heyndrickx
Journal:  Eur Heart J Case Rep       Date:  2021-05-29

2.  Current perspectives on mechanical circulatory support.

Authors:  Rene Schramm; Michiel Morshuis; Michael Schoenbrodt; Jochen Boergermann; Kavous Hakim-Meibodi; Masatoshi Hata; Jan F Gummert
Journal:  Eur J Cardiothorac Surg       Date:  2019-06-01       Impact factor: 4.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.